- Agilent isn't a conventionally cheap stock, but should offer above-average revenue growth and margin expansion over the next five to 10 years, with leverage to several growth segments with biopharma.
- Agilent has been gaining share in instruments and demand should improve as lab activities and budgets normalize after the pandemic, with automation a longer-term growth driver.
- Lab services is an attractive growth opportunity, and Agilent is an early mover in providing complete workflow solutions for a monthly fee.
- Oligonucleotide production is a growth opportunity as RNAi biotechs target more mass-market diseases, while other therapeutic areas like gene editing and gene therapy offer above-average growth.
- Agilent looks like a growth stock with a valuation that isn't totally detached from the underlying reality of its margins and future cash flows.
For further details see:
Agilent Leveraged To Post-Pandemic Recovery And Advanced Drug Discovery And Production